Skip to content
Open access

Structure–Activity Relationship for Inflammasome Inhibition by Thiomuscimol

Aug 2026 · International Journal of Molecular Sciences · Vol 27, pp. 7235 · 0 citations · 27 references
Medicine

TL;DR

Key structural features required for thiomuscimol-mediated inflammasome inhibition are identified and a framework for future studies to define its mechanism of action and guide the development of improved inhibitors is provided.

Abstract

Inflammasomes are central mediators of innate immune defense but can also drive pathological inflammation and pyroptotic cell death in numerous diseases. While several small-molecule inhibitors have been described, many selectively target individual inflammasomes or act through the adaptor protein ASC, leaving ASC-independent pathways unaffected. We previously identified thiomuscimol as a broad-spectrum inflammasome inhibitor that blocks both ASC-dependent and ASC-independent activation, although the structural basis for this activity remains unclear. Here, we examined the structure–activity relationship of thiomuscimol using related compounds and synthetic analogs. In primary macrophages, inflammasome activation and pyroptosis were assessed by live cell imaging of ASC speck formation, gasdermin D-mediated dye uptake, and cellular ATP levels. Structurally related sulfur-containing molecules, including taurine and isothiazole, failed to inhibit inflammasome activation, indicating that neither the sulfur in an electron-rich environment nor the heterocyclic scaffold confer activity. Replacement of the primary amine with a carbonyl group abolished activity, whereas substitution with a secondary amine preserved inhibitory potency comparable to thiomuscimol. Incorporation of the amine into an annulated piperidine ring reduced potency and revealed sensitivity to the precise positioning of the amine within the ring. Together, these findings identify key structural features required for thiomuscimol-mediated inflammasome inhibition and provide a framework for future studies to define its mechanism of action and guide the development of improved inhibitors.

Read PDF

Similar papers

Review Open access Aug 2026

Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects

This review systematically summarizes the molecular regulatory mechanisms of pyroptosis, encompassing classical and non-classical inflammasome pathways, activation and modulation of gasdermin proteins, and the intricate signaling networks involved.

Yi Shen, Qiang-Qiang Zheng, Yang Yuan et al. · 0 citations
Sep 2026

DPP3 restrains the non-canonical inflammasome through PEBP1 cleavage.

Findings provide a perspective for understanding the molecular regulatory process of the non-canonical inflammasome in sepsis and positively regulated the activation of the non-canonical inflammasome by inhibiting the activity of dipeptidyl peptidase 3.

Meng-Qian Li, Jia-Jia Zheng, Chun Kong et al. · 0 citations
Review Aug 2026

Role of pyroptosis in melanoma: Molecular mechanisms and therapeutic potentials

Emerging evidence now reveals that pyroptosis exhibits dual functionality through its capacity to reshape the tumor immune microenvironment, and the cytotoxicity and immunotherapeutic response rate of cytotoxic T cells are significantly enhanced by activation of the T cell receptor signaling pathway and cytokine networ...

Xiao-Han Zhang, Ke Zhang, Xue-Chun Qu et al. · 0 citations
Open access Sep 2026

Structural mechanisms for ATP-mediated inhibition of human NLRP6 inflammasome.

Inflammasomes ignite innate immune defense in response to infectious pathogens and noninfectious dangers, primarily through sensors composed of nucleotide-binding domain (NBD), leucine-rich repeat (LRR)-containing (NLR) family proteins. NLRP6 is an inflammasome sensor that plays critical roles in regulating intestinal...

Zhen Cui, Qi Sheng, Minsoo Son et al. · 0 citations
Aug 2026

Vilazodone inhibits NLRP3 inflammasome assembly by targeting the NACHT domain and alleviates inflammatory disease.

The NLRP3 inflammasome plays a central role in innate immunity and inflammatory diseases, yet effective inhibitors remain limited. Here, we identified vilazodone, an FDA-approved antidepressant, as a potent inhibitor of NLRP3 inflammasome activation by small-molecule screening. Vilazodone significantly suppressed IL-1β...

Xiang-Yu Yang, Gui-Fang Xiong, Jie Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.